Intercept Pharma (ICPT) Receives FDA Orphan Drug Designation

Intercept Pharma (ICPT) Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis

Intercept Pharma (ICPT) Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Austria , Vienna , Wien , United States , M Michelle Berrey , , Office Of Orphan Drug Products , Intercept Pharmaceuticals Inc , Nasdaq , Drug Administration , Research Development , Chief Medical Officer , Orphan Drug Products , Bezafibrate Fixed Dose Combinationintercept ,